Cellectis

Cellectis Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Cellectis (CLLS) as of Nov 19, 2026 is 59.38 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -60.13 % — a change of -198.76% (higher).

Cash Conversion

59.38 %

YoY

-198.76%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Cellectis is 2025 59.38 % . Cash Conversion Rate (OCF/Net Income) of Cellectis was 2024 -60.13 % . It decreases by -198.76% higher compared to the previous year.

The Cellectis Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
86.59 USD
Jan 1, 2019
76.24 USD
Jan 1, 2020
110.60 USD
Jan 1, 2021
121.19 USD
Jan 1, 2022
88.61 USD
Jan 1, 2023
24.49 USD
Jan 1, 2024
-60.13 USD
Jan 1, 2025
59.38 USD
The Cellectis Cash Conversion history
YEARCash ConversionYoY
59.38 %-198.76%
-60.13 %-345.55%
24.49 %-72.36%
88.61 %-26.89%
121.19 %+9.58%
110.60 %+45.06%
76.24 %-11.94%
86.59 %+64.42%
52.66 %+8.27%
48.64 %-408.77%
-15.75 %-100.01%
208,627.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellectis Stock analysis

What does Cellectis do? Cellectis SA develops gene-editing based products for immuno-oncology and gene therapy, targeting specific cancer indications. The company's product portfolio includes BALLI-01 for relapsed or refractory acute lymphoblastic leukemia (r/r ALL), NatHaLi-01 for relapsed or refractory B-cell Non-Hodgkin's Lymphoma (B-NHL), ALPHA3 for Large B-Cell Lymphoma (LBCL), TRAVERSE for advanced or metastatic clear cell renal cell carcinoma (RCC), and Melanoma for unresectable or metastatic melanoma. These products are in clinical development stages, focusing on evaluating safety, expansion, persistence, and clinical activity in targeted patient populations. The company operates as a clinical stage biotechnology firm with a focus on allogeneic chimeric antigen receptor T-cell therapies and gene therapy product candidates. Cellectis SA's primary revenue stream comes from the development and potential future commercialization of its gene-editing therapies. The company is currently in the clinical stage, meaning it does not yet have commercialized products generating revenue. Instead, it relies on funding from research grants, partnerships, and equity financing to support its ongoing clinical trials and development activities. The company's focus on specific cancer types such as ALL, B-NHL, LBCL, RCC, and melanoma targets patients with unmet medical needs, positioning itself for potential future partnerships with pharmaceutical companies for further development and commercialization. The company's target segments include patients with relapsed or refractory cancers, specifically those suffering from r/r ALL, B-NHL, LBCL, RCC, and melanoma. These segments represent significant unmet medical needs in oncology, with Cellectis SA aiming to provide novel therapeutic options through its gene-editing platform. The company's development pipeline is designed to address these specific indications, with each product candidate targeting a distinct patient population requiring innovative treatments. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

Cash Conversion Rate (OCF/Net Income) of Cellectis is 59.38 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Cellectis changed from -60.13 % to 59.38 %, representing a -198.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Cellectis since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Cellectis with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cellectis

All Key Metrics — Cellectis